CCR5 inhibitors: emergence, success, and challenges

Bibliography

• Mitsuya H, Weinhold KJ, Furman PA, 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-100
   PubMed Web of Science ®Google Scholar
• Mitsuya H, Erickson J. Discovery and development of antiretroviral therapeutics for HIV infection. In: Merigan TC, Bartlet JG, Bolognesi D, editors. Textbook of AIDS Medicine. Williams & Wilkins; Baltimore: 1999. p. 751-80
   Google Scholar
• Murphy EL, Collier AC, Kalish LA, Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26
   PubMed Web of Science ®Google Scholar
• Hogg R, Lima V, Sterne JA, Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Hamouda O, Sannes M, Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-9
   PubMed Web of Science ®Google Scholar
• Walensky RP, Paltiel AD, Losina E, The survival benefits of AIDS treatment in the United States. J Infect Dis 2006;194:11-19
   PubMed Web of Science ®Google Scholar
• Gupta R, Hill A, Sawyer AW, Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008;47:712-28
   PubMed Web of Science ®Google Scholar
• Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003;9:839-43
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Kaufmann G, Sendi P, Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:1159-66
   PubMed Web of Science ®Google Scholar
• Bleul CC, Farzan M, Choe H, The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-33
   PubMed Web of Science ®Google Scholar
• Trkola A, Dragic T, Arthos J, CD4-dependent, antibody- sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 1996;384:184-7
   PubMed Web of Science ®Google Scholar
• Deng H, Liu R, Ellmeier W, Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6
   PubMed Web of Science ®Google Scholar
• Wu L, Gerard NP, Wyatt R, CD4- induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384:179-83
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Rucker J, Yi Y, A dual-tropic primary HIV-1 isolate that uses fusin and the beta- chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58
   PubMed Web of Science ®Google Scholar
• Choe H, Farzan M, Sun Y, The beta- chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48
   PubMed Web of Science ®Google Scholar
• Dragic T, Litwin V, Allaway GP, HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5. Nature 1996;381:667-73
   PubMed Web of Science ®Google Scholar
• Alkhatib G, Combadiere C, Broder CC, CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8
   PubMed Web of Science ®Google Scholar
• Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7
   PubMed Web of Science ®Google Scholar
• Rizzuto CD, Wyatt R, Hernandez-Ramos N, A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-53
   PubMed Web of Science ®Google Scholar
• Poignard P, Saphire EO, Parren PW, Burton DR. Gp120: biologic aspects of structural features. Annu Rev Immunol 2001;19:253-74
   PubMed Web of Science ®Google Scholar
• Kwong PD, Wyatt R, Robinson J, Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59
   PubMed Web of Science ®Google Scholar
• Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003;348:2228-38
   PubMed Web of Science ®Google Scholar
• Jahn R, Lang T, Sudhof TC. Membrane fusion. Cell 2003;112:519-33
   PubMed Web of Science ®Google Scholar
• Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73
   PubMed Web of Science ®Google Scholar
• Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4
   PubMed Web of Science ®Google Scholar
• Littman DR. Chemokine receptors: keys to AIDS pathogenesis? Cell 1998;93:677-80
   PubMed Web of Science ®Google Scholar
• Hoffman TL, Doms RW. Chemokines and coreceptors in HIV/SIV-host interactions. AIDS 1998;12(Suppl A):S17-26
   PubMedGoogle Scholar
• Doranz BJ, Berson JF, Rucker J, Doms RW. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res 1997;16:15-28
   PubMed Web of Science ®Google Scholar
• Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997;11:S3-16
   PubMed Web of Science ®Google Scholar
• Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700
   PubMed Web of Science ®Google Scholar
• Connor RI, Sheridan KE, Ceradini D, Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-8
   PubMed Web of Science ®Google Scholar
• de Roda Husman AM, Schuitemaker H. Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol 1998;6:244-9
   PubMed Web of Science ®Google Scholar
• O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000;177:99-111
   PubMed Web of Science ®Google Scholar
• Samson M, Libert F, Doranz BJ, Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5
   PubMed Web of Science ®Google Scholar
• Dean M, Carrington M, Winkler C, Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77
   PubMed Web of Science ®Google Scholar
• Glass WG, McDermott DH, Lim JK, CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40
   PubMed Web of Science ®Google Scholar
• Bracci PM, Skibola CF, Conde L, Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma 2010;51:497-506
   PubMed Web of Science ®Google Scholar
• AIDS epidemic update. World Health Organization. Available from: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/jc1700 _epi_update_2009_en.pdf [Last accessed 12 December 2011]
   Google Scholar
• Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. UNAIDS. Available from: http://www.unaids.org/globalreport/Global_report.htm [Last accessed 12 December 2011]
   Google Scholar
• Impact of the Global Financial and Economic Crisis on the AIDS Response. 25th Meeting of the UNAIDS Programme Coordinating Board: UNAIDS, 2009. Available from: http://www.unaids.org/en/ [Last accessed 12 December 2011]
   Google Scholar
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) (January 10, 2011)
   Google Scholar
• Chapman D, Valdez H, Lewis M, Clinical, virologic, and immunologic characteristics of patients with discordant phenotypic and genotypic co-receptor tropism test results. Paper presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA
   Google Scholar
• McGovern RA, Thielen A, Mo T, Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010;24:2517-25
   PubMed Web of Science ®Google Scholar
• Vandekerckhove LP, Wensing AM, Kaiser R, European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11:394-407
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico AL, Garzino-Demo A, Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-15
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32
   PubMed Web of Science ®Google Scholar
• Strizki JM, Xu S, Wagner NE, SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-23
   PubMed Web of Science ®Google Scholar
• Tagat JR, McCombie SW, Nazareno D, Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl) phenyl]ethyl- 3(S)-methyl-1- piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004;47:2405-8
   PubMed Web of Science ®Google Scholar
• Maeda K, Nakata H, Koh Y, A spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 HIV-1 in vitro. J Virol 2004;78:8654-62
   PubMed Web of Science ®Google Scholar
• Baba M, Nishimura O, Kanzaki N, A small- molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-03
   PubMed Web of Science ®Google Scholar
• Seto M, Aikawa K, Miyamoto N, Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem 2006;49:2037-48
   PubMed Web of Science ®Google Scholar
• Parra J, Portilla J, Pulido F, Clinical utility of maraviroc. Clin Drug Investig 2011;31:527-42
   PubMed Web of Science ®Google Scholar
• Daniel R, Kuritzkes MD. HIV-1 Entry Inhibitors: an Overview. Curr Opin HIV AIDS 2009;4:82-7
   PubMedGoogle Scholar
• Fatkenheuer G, Pozniak AL, Johnson MA, Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Nelson M, Lazzarin A, Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-55
   PubMed Web of Science ®Google Scholar
• What is Trofile™. Trofile-Monogram Biosciences. Available from: http://www.trofileassay.com/what_is_trofile.html [Last accessed 12 December 2011]
   Google Scholar
• Perno CF, Craig C, Taylor S, Efficacy and Viral Resistance Are Comparable when Maraviroc Is Administered Once Daily or Twice Daily with Boosted Protease Inhibitors in Treatment-experienced Patients [abstract PE7.3/4]. 13th European AIDS Conference; 12 – 15 October 2011; Belgrade, Serbia
   Google Scholar
• Hardy D, Reynes J, Konourina I, Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [abstract #792]. 15th Conference on Retroviruses and Opportunistic Infections; 3 – 6 February 2008; Boston, MA
   Google Scholar
• Hoepelman IM, Ayoub A, Heera J. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the Maraviroc Clinical Development Programme [abstract LBP7.9/1]. 11th European AIDS Conference/EACS; 24 – 27 October 2007; Madrid, Spain
   Google Scholar
• Saag M, Ive P, Heera J, A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study [abstract #WESS104]. 4th IAS conference; 22 – 25 July 2007; Sydney, Australia
   Google Scholar
• Cooper DA, Heera J, Goodrich J, Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-13
   PubMed Web of Science ®Google Scholar
• Heera J, Saag M, Ive P, Virological correlates associated with treatment failure at week 48 in the phase III study of maraviroc in treatment naive patients [abstract #40LB]. 15th Conference on Retroviruses and Opportunistic Infections; 3 – 6 February 2008; Boston, MA
   Google Scholar
• Hardy WD, Gulick RM, Mayer H, Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010;55:558-64
   PubMed Web of Science ®Google Scholar
• Sierra-Madero J, Di Perri G, Wood R, Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010;11:125-32
   PubMed Web of Science ®Google Scholar
• Gulick RM, Su Z, Flexner C, Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12
   PubMed Web of Science ®Google Scholar
• McCarthy MC, Suleiman J, Diaz R, Vicriviroc Long-Term Safety and Efficacy: 96-Week Results from the VICTOR-E1 Study [abstract H-923]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009); 12 – 15 September 2009; San Francisco, CA
   Google Scholar
• Gathe J, Diaz R, Fatkenheuer G, Phase III Trials of Vicriviroc in Treatment-experienced Subjects Demonstrate Safety but Not Significantly Superior Efficacy over Potent Background Regimens Alone [abstract 54LB]. 17th Conference on Retroviruses & Opportunistic Infections; 16 – 19 February 2010; San Francisco, CA
   Google Scholar
• Nakata H, Maeda K, Miyakawa T, Potent anti-R5-HIV-1 effects of a CCR5 antagonist AK602 in a novel hu-PBMC-Non-Obese-Diabetic-SCID, IL-2Rg-Chain-Knocked-Out AIDS mouse model. J Virol 2005;79:2087-96
   PubMed Web of Science ®Google Scholar
• Lalezari J, Thompson M, Kumar P, Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005;19:1443-8
   PubMed Web of Science ®Google Scholar
• Nichols WG, Steel HM, Bonny T, Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858-65
   PubMed Web of Science ®Google Scholar
• Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team. Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother 2009;53:1116-23
   PubMed Web of Science ®Google Scholar
• Cohen C, DeJesus E, Mills A, Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days monotherapy [abstract TUAB106]. 4th IAS Conference on AIDS Pathogenesis, Treatment and Prevention; 22 – 25 July 2007; Sydney, Australia
   Google Scholar
• Product Pipeline. Incyte Corp. Available from: http://www.incyte.com/drugs_product_pipeline.html [Last accessed 13 December 2011]
   Google Scholar
• Klibanov OM, Williams SH, Iler CA. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs 2010;11:940-50
   PubMed Web of Science ®Google Scholar
• Pipeline, Discovery & Development. Tobira Therapeutics. Available from: http://www.tobiratherapeutics.com/discovery.php [Last accessed 13 December 2011]
   Google Scholar
• Westby M, Smith-Burchnell C, Mori J, Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-71
   PubMed Web of Science ®Google Scholar
• Pugach P, Marozsan AJ, Ketas TJ, HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361:212-28
   PubMed Web of Science ®Google Scholar
• LaBranche C, Kitrinos K, Howell R, Clonal analysis of in vitro-derived viruses with reduced susceptibility to aplaviroc (873140, APL) shows wide ranges in IC50 and sequence changes [abstract 9]. Targeting HIV Entry—1st International Workshop; 2 – 3 December 2005; Bethesda, MD
   Google Scholar
• Lewis M. A genotypic analysis of HIV-1 sequences from emerging resistant virus after in vitro serial passage with the CCR5 antagonist maraviroc (UK-427,857) [abstract 91]. 3rd European HIV Drug Resistance Workshop; 4 – 7 April 2005; Athens, Greece
   Google Scholar
• Westby M. Maraviroc (MVC, UK-427,857)-resistant HIV-1 variants, selected by serial passage, are sensitive to CCR5 antagonists (GW873140, Schering-C, Schering-D) and T-20 (enfuvirtide) [abstract 65]. XIV International Drug Resistance Workshop; 7 – 11 June 2005; Quebec City, Canada
   Google Scholar
• Craig C, Heera J, Lewis M, Mechanisms of virologic failure with maraviroc in treatment-naive HIV-1-infected patients through 96 weeks [abstract 536]. 17th Conference on Retroviruses and Opportunistic Infections; 16 – 19 February 2010; San Francisco, CA
   Google Scholar
• Waters L, Scourfield A, Marcano M, The evolution of co-receptor tropism in patients interrupting suppressive HAART [abstract 439a]. 16th Conference on Retroviruses and Opportunistic Infections; 8 – 11 February 2009; Montreal, Canada
   Google Scholar
• Whitcomb JM, Huang W, Fransen S, Development and characterization of a novel single-cycle recombinant virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566-75
   PubMed Web of Science ®Google Scholar
• Asmuth DM, Goodrich J, Cooper DA, CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010;54:394-7
   PubMed Web of Science ®Google Scholar
• Cuzin L, Trabelsi S, Mouillot G, ANRS 145 Marimuno Study: a Multi-centre Prospective Pilot Study Evaluating Intensification of Stable Antiviral Therapy with Maraviroc in HIV-1-infected Patients with Insufficient Immune Restoration Despite Persistently Controlled Viral Replication [abstract PS1/6]. 13th European AIDS Conference; 12 – 15 October 2011; Belgrade, Serbia
   Google Scholar
• Dragic T, Trkola A, Thompson DA, A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-44
   PubMed Web of Science ®Google Scholar
• Tsamis F, Gavrilov S, Kajumo F, Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003;77:5201-8
   PubMed Web of Science ®Google Scholar
• Maeda K, Das D, Ogata-Aoki H, Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 2006;281:12688-98
   PubMed Web of Science ®Google Scholar
• Maeda K, Das D, Yin P, Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights to mechanism of allosteric inhibition. J Mol Biol 2008;381:956-74
   PubMed Web of Science ®Google Scholar
• Kondru R, Zhang J, Ji C, Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008;73:789-800
   PubMed Web of Science ®Google Scholar
• Shahlaei M, Madadkar-Sobhani A, Mahnam K, Homology modeling of human CCR5 and analysis of its binding properties through molecular docking and molecular dynamics simulation. Biochim Biophys Acta 2011;1808:802-17
   PubMed Web of Science ®Google Scholar
• Garcia-Perez J, Rueda P, Alcami J, Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 2011;286:33409-21
   PubMed Web of Science ®Google Scholar
• Hall SE, Mao A, Nicolaidou V, Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 2009;75:1325-36
   PubMed Web of Science ®Google Scholar
• Wu B, Chien EY, Mol CD, Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010;330:1066-71
   PubMed Web of Science ®Google Scholar